Public consultation: Target Product Profiles to develop rapid low-cost test for gonorrhoea and chlamydia diagnosis and antibiotic resistance testing for gonorrhoea
Target Product Profiles (TPPs)
Feedback Survey - Public Consultation
About 87 million new gonorrhoea infections occur every year based on the new WHO estimates. It is of concern that gonorrhoea has developed resistance to almost all antibiotics recommended for treating it. Antibiotic stewardship to conserve current treatment and future treatment is critical to reduce the transmission and prevent complications and long-term sequelae.
The World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND), are requesting your feedback on two target product profiles (TPPs) for improved antimicrobial stewardship of gonorrhoea treatment. See attached the latest versions of the TPP drafts. These new TPPs aim to incorporate technology advancements over the past years that may enable development of:
- a rapid, low-cost test to differentiate gonorrhoea and chlamydial infection with sufficient performance to support uptake and wide-scale use in community settings and
- a comprehensive test to determine antibiotic resistance of gonorrhoea to guide treatment decisions.
The goal of these TPPs is to define technologies that could improve upon the syndromic management of STI infections to inform clinical treatment decisions. An overview of the entire TPP development process is summarized in the attached document.
Any proposed revisions during the public consultation will be considered by the TPP working group before finalizing it. The final TPPs will be used for the diagnostic development to conserve new treatment for gonorrhoea.